Sandoz Vinorelbine 10 mg/1 ml, 50 mg/5 ml Concentrate for solution for infusion
PDF Leaflet Revision Date: 22 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced inoperable NSCLC and metastatic breast cancer.
Dosage (summary)
25-30 mg/mu00b2 weekly for single-agent; 30 mg/mu00b2 weekly for metastatic disease.
Special Populations
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; effective contraception required during treatment.
Key Drug Interactions
- Phenytoin
- Itraconazole
- Cisplatin
- Mitomycin C
Contraindications
- Hypersensitivity to vinorelbine
- Severe hepatic insufficiency
- Severe granulocytopenia
- Pregnancy and lactation
Common side effects
- Neutropenia
- Nausea
- Vomiting
- Fatigue
- Constipation
Counselling Points
- Avoid contact with eyes
- Report signs of infection
- Use gloves when handling
- Monitor for signs of neuropathy
Serious warnings
- Cytotoxic drug; requires monitoring of blood counts
- Risk of extravasation injury
- Potential for severe allergic reactions
Important Disclaimer
The Sandoz Vinorelbine 10 mg/1 ml, 50 mg/5 ml Concentrate for solution for infusion professional information leaflet below is the property of Sandoz Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
